Study Summary: This study tests a vaccine called VGX-3100 made from DNA for treating high-grade anal lesions in HIV-positive people. High-grade anal lesions are abnormal tissue growths that can become cancerous. The vaccine helps the immune system fight these lesions, and electroporation is used to help cells absorb the vaccine better. Electroporation involves using a small electric pulse to open pores in the cells.
- Duration: Participants receive four doses over 24 weeks and will be monitored for up to 72 weeks.
- Visits: Regular visits for dose administration and follow-up checks.
- Risks: Possible side effects from the vaccine or electroporation.
Eligibility: Participants must have HIV, certain types of high-grade anal lesions, and no recent cancer treatments. Women must not be pregnant, and everyone must agree to use birth control during the study. Participants with certain medical issues or a history of specific cancers are not eligible.
How understandable was the trial content above?
Hard to understand
Easy to understand